Twin Lakes Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Twin Lakes Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-139,397	Closed	-$3.3M	–	250
2022 Q1	$3.3M	Buy	139,397 +817	+0.6%	+$23K	1.86%	18
2021 Q4	$4.74M	Sell	138,580 -707	-0.5%	-$22.3K	2.53%	9
2021 Q3	$2.47M	Sell	139,287 -4,153	-3%	-$177K	1.45%	25
2021 Q2	$6.44M	Buy	143,440 +556	+0.4%	+$18.4K	3.58%	6
2021 Q1	$3.7M	Buy	142,884 +401	+0.3%	+$10.1K	2.28%	13
2020 Q4	$2.87M	Buy	+142,483	New	+$3.07M	2.05%	17

Other funds holding PTGX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Twin Lakes Capital Management's PTGX Position: Q2 2022 in Review

Twin Lakes Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 139,397 shares — an estimated $3.3M sold.

Twin Lakes Capital Management first reported a position in PTGX in Q4 2020 and held it in 6 quarters. The position peaked at $6.44M in Q2 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

Twin Lakes Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
Twin Lakes Capital Management sold 139,397 Protagonist Therapeutics shares in Q2 2022, an estimated $3.3M.
Twin Lakes Capital Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 6 quarters.
Twin Lakes Capital Management's Protagonist Therapeutics position peaked at $6.44M in Q2 2021.
130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Twin Lakes Capital Management's 13F filing for Q2 2022, filed 18 Aug 2022.